Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Novolog Mix 70/30
Generic Name
Insulin Aspart
Active Ingredient
Insulin AspartCategory
Insulin Analog [EPC]
Variants
7
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 100 [iU]/mL | INJECTION, SUSPENSION | SUBCUTANEOUS | 0169-3696 |
| 100 [iU]/mL | INJECTION, SUSPENSION | SUBCUTANEOUS | 70518-2119 |
| 100 [iU]/mL | INJECTION, SUSPENSION | SUBCUTANEOUS |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Novolog Mix 70/30, you must consult a qualified healthcare professional.
| 100 [iU]/mL | INJECTION, SUSPENSION | SUBCUTANEOUS | 0169-3685 |
| 100 [iU]/mL | INJECTION, SUSPENSION | SUBCUTANEOUS | 0169-2201 |
| 100 [iU]/mL | INJECTION, SUSPENSION | SUBCUTANEOUS | 0169-2200 |
| 100 [iU]/mL | INJECTION, SUSPENSION | SUBCUTANEOUS | 50090-4085 |
Detailed information about Novolog Mix 70/30
Insulin Aspart is a rapid-acting insulin analog used to improve glycemic control in adults and children with diabetes mellitus. It belongs to the insulin analog [EPC] class and is typically administered via subcutaneous injection or continuous pump infusion.
Dosage of Insulin Aspart must be highly individualized based on the patient's metabolic needs, blood glucose monitoring results, and glycemic control goals. It is typically administered subcutaneously in the abdominal wall, thigh, or upper arm.
Insulin Aspart is approved for use in pediatric patients with diabetes mellitus. For children with Type 1 diabetes, the dosing is similar to adults, calculated based on body weight, activity levels, and carbohydrate intake. Healthcare providers often use Insulin Aspart in children as young as 2 years old. Because children may have unpredictable eating habits, Insulin Aspart is particularly useful because it can be administered immediately after a meal if the child's intake is uncertain.
The kidneys play a significant role in the clearance of insulin. Patients with renal impairment may require lower doses of Insulin Aspart because the drug remains in the system longer. Frequent blood glucose monitoring is essential in this population to prevent hypoglycemia.
The liver is a primary site for insulin metabolism. In patients with hepatic impairment, insulin requirements may be reduced. Close clinical monitoring and dose titration are necessary to ensure safety and efficacy.
Geriatric patients (65 years and older) may be at increased risk for hypoglycemia due to age-related declines in renal function and potential cognitive changes. Dosing should be conservative, often starting at the lower end of the range, with gradual adjustments.
If a dose of Insulin Aspart is missed during a meal, check your blood glucose level immediately. If it is shortly after the meal, you may be able to take the dose. However, if several hours have passed, your healthcare provider may advise you to wait until the next meal or follow a specific "correction factor" protocol. Do not double the dose to make up for a missed one, as this significantly increases the risk of severe hypoglycemia.
An overdose of insulin can lead to life-threatening hypoglycemia (low blood sugar) and hypokalemia (low potassium). Symptoms of mild hypoglycemia include sweating, shakiness, confusion, and palpitations. Severe overdose can lead to seizures, coma, or death.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or change your insulin brand without medical guidance.
As with all insulin therapies, the most frequent adverse reaction associated with Insulin Aspart is hypoglycemia. Clinical trials indicate that nearly all patients using insulin will experience some degree of low blood sugar.
Insulin Aspart is a potent medication that requires careful management. The most critical safety concern is the risk of hypoglycemia. Patients must be educated on the symptoms of low blood sugar and the proper way to treat it. Furthermore, Insulin Aspart should never be shared between patients, even if the needle is changed, as this poses a risk for the transmission of blood-borne pathogens.
No FDA black box warnings for Insulin Aspart. However, safety labels emphasize that changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose patients to hypoglycemia or hyperglycemia.
There are no absolute drug-drug contraindications where Insulin Aspart must never be used; however, certain combinations require extreme caution. The use of Insulin Aspart during episodes of acute hypoglycemia is contraindicated.
Insulin Aspart is strictly contraindicated in the following scenarios:
Healthcare providers must perform a careful risk-benefit analysis in the following conditions:
Insulin Aspart is generally considered safe for use during pregnancy. According to the FDA, data from randomized controlled trials have not identified a drug-associated risk of major birth defects or adverse maternal or fetal outcomes. Maintaining strict glycemic control is essential during pregnancy, as poorly controlled diabetes increases the risk of macrosomia (large baby), neonatal hypoglycemia, and preeclampsia. Insulin Aspart is often preferred over regular human insulin in pregnancy due to its superior postprandial glucose control. Dosing requirements often change throughout pregnancy: they may decrease in the first trimester and significantly increase during the second and third trimesters.
Insulin Aspart is excreted in human milk, but it is a protein that is digested in the infant's gastrointestinal tract. Therefore, it is not expected to cause adverse effects in the nursing infant. Breastfeeding mothers may require dose adjustments, as lactation can lower blood glucose levels and increase energy expenditure. It is considered safe for use by breastfeeding women.
Insulin Aspart is FDA-approved for use in pediatric patients with diabetes mellitus. Clinical studies have demonstrated that it is effective and well-tolerated in children as young as 2 years of age. In the pediatric population, the rapid onset of action is particularly beneficial for children with unpredictable eating patterns, as the dose can be administered immediately after a meal based on the actual amount of carbohydrates consumed. Growth and development should be monitored, as insulin requirements change during puberty due to hormonal shifts.
Insulin Aspart is a rapid-acting recombinant human insulin analog. Its primary mechanism is binding to the human insulin receptor (a tyrosine kinase receptor). This binding triggers a cascade of intracellular signaling, including the translocation of glucose transporter proteins (GLUT4) to the cell membrane of muscle and adipose tissues. This facilitates the influx of glucose into the cells. Additionally, Insulin Aspart suppresses hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis, and it promotes the storage of glucose as glycogen in the liver.
The pharmacodynamic profile of Insulin Aspart is characterized by a rapid onset and a short duration of action. After subcutaneous injection, the glucose-lowering effect typically begins within 10 to 20 minutes. The maximum effect is reached between 1 and 3 hours post-injection. The duration of action is approximately 3 to 5 hours. This profile closely mimics the physiological insulin secretion in response to a meal, providing better control of postprandial glucose compared to regular human insulin.
| Parameter | Value |
Common questions about Novolog Mix 70/30
Insulin Aspart is a rapid-acting insulin analog used to improve blood sugar control in adults and children with Type 1 and Type 2 diabetes mellitus. It is specifically designed to manage the spikes in blood glucose that occur after eating a meal. By mimicking the body's natural insulin response, it helps transport sugar from the bloodstream into the cells for energy. It can be used as part of a daily injection regimen or in a continuous insulin pump. Healthcare providers typically prescribe it alongside a long-acting basal insulin for comprehensive 24-hour coverage.
The most common side effect of Insulin Aspart is hypoglycemia, or low blood sugar, which can cause symptoms like shakiness, sweating, and confusion. Other frequent side effects include injection site reactions such as redness, itching, or swelling where the needle entered the skin. Some patients may notice weight gain as their blood sugar control improves and the body begins to store glucose properly. Lipodystrophy, which is a change in the thickness of the skin at the injection site, can also occur if sites are not rotated. Most minor side effects resolve as the body adjusts to the medication.
Alcohol consumption while using Insulin Aspart requires extreme caution because it can lead to unpredictable changes in blood sugar. Alcohol can inhibit the liver's ability to release glucose, which significantly increases the risk of severe and delayed hypoglycemia. Conversely, some alcoholic beverages contain high amounts of sugar and may cause blood glucose levels to rise initially. If you choose to drink, it is recommended to do so in moderation and always consume food with your drink. You should also monitor your blood sugar levels more frequently, including before going to bed, to prevent nocturnal hypoglycemia.
Insulin Aspart is generally considered safe and is often the preferred choice for managing diabetes during pregnancy. Clinical data have shown that it does not increase the risk of birth defects or harm to the developing fetus compared to other types of insulin. Maintaining tight blood sugar control is vital for the health of both the mother and the baby, as high blood sugar can lead to complications like preeclampsia or macrosomia. Dosing requirements often change significantly throughout the various trimesters of pregnancy. Always work closely with your healthcare provider to adjust your insulin plan if you are pregnant or planning to become pregnant.
Insulin Aspart is a rapid-acting insulin, meaning it starts to lower blood sugar very quickly, typically within 10 to 20 minutes after injection. Because of this fast onset, it should be taken immediately before a meal (within 5 to 10 minutes) or even shortly after you have started eating. The peak effect occurs between 1 and 3 hours after administration, which coincides with the time food is being digested. The total duration of action is relatively short, usually lasting between 3 and 5 hours. This short duration helps reduce the risk of 'insulin stacking' or low blood sugar between meals.
You should never stop taking Insulin Aspart suddenly without consulting your healthcare provider, especially if you have Type 1 diabetes. Stopping insulin can lead to dangerously high blood sugar levels and a life-threatening condition called diabetic ketoacidosis (DKA). DKA occurs when the body lacks enough insulin to use sugar for energy and begins breaking down fat too quickly, leading to a buildup of ketones in the blood. If you need to change your medication or are having trouble affording your insulin, talk to your doctor immediately. They can help you transition to a different therapy safely.
If you miss a dose of Insulin Aspart during a meal, check your blood sugar level to see if it is elevated. If you realize the mistake shortly after finishing your meal, you may be able to take your usual dose. However, if several hours have passed, taking the full dose could lead to hypoglycemia later in the day. In such cases, follow the specific instructions provided by your healthcare team, which may involve taking a smaller 'correction dose' or simply waiting until your next meal. Never double your dose to compensate for a missed one, as this is a major cause of severe low blood sugar.
Weight gain is a common side effect of all insulin therapies, including Insulin Aspart. This happens for two main reasons: first, insulin is an anabolic hormone that promotes the storage of energy in the form of fat and muscle. Second, as Insulin Aspart effectively lowers your blood sugar, glucose is no longer being lost through your urine (glycosuria), meaning your body is absorbing and utilizing those calories. To manage weight while on insulin, it is important to follow a balanced diet and engage in regular physical activity. Discuss weight management strategies with your doctor or a registered dietitian.
Insulin Aspart can be taken with many other medications, but some drugs can change how well insulin works. For example, steroids like prednisone can raise blood sugar, requiring higher doses of insulin, while certain blood pressure medications like ACE inhibitors can lower blood sugar, increasing the risk of hypoglycemia. Beta-blockers are particularly notable because they can hide the symptoms of low blood sugar, such as a fast heartbeat. Always provide your healthcare provider with a complete list of all prescription drugs, over-the-counter medicines, and herbal supplements you are taking. This allows them to adjust your insulin dose for maximum safety.
While insulin is a biologic medication and does not have 'generics' in the traditional sense, Insulin Aspart is available in lower-cost versions known as biosimilars or follow-on biologics. For example, there are unbranded versions of Insulin Aspart (Insulin Aspart-vgrx) that are biologically highly similar to the brand-name NovoLog and are often available at a lower price point. These versions are FDA-approved and meet the same rigorous standards for safety and effectiveness as the original brand. Availability may vary depending on your pharmacy and insurance coverage. Talk to your pharmacist to see if a more affordable version of Insulin Aspart is available for you.
Other drugs with the same active ingredient (Insulin Aspart)
> Warning: Stop taking Insulin Aspart and call your doctor or emergency services immediately if you experience any of these serious symptoms.
There are currently no FDA Black Box Warnings specifically for Insulin Aspart. However, all insulin products carry a general warning regarding the risk of life-threatening hypoglycemia and the potential for medication errors (e.g., confusing rapid-acting insulin with long-acting insulin).
Report any unusual symptoms or persistent side effects to your healthcare provider. Monitoring your body's response to insulin is a lifelong component of diabetes management.
Effective therapy with Insulin Aspart requires regular monitoring of several clinical parameters:
Your ability to concentrate and react may be impaired if you have hypoglycemia. This may present a risk in situations where these abilities are especially important, such as driving a car or operating heavy machinery. Patients should check their blood sugar before driving and avoid driving if they feel any symptoms of hypoglycemia.
Alcohol may increase or decrease the blood glucose-lowering effect of Insulin Aspart. Consumption of alcohol while on insulin therapy increases the risk of delayed hypoglycemia, as alcohol inhibits the liver's ability to release glucose into the bloodstream. Patients should discuss alcohol consumption with their doctor and monitor blood sugar levels closely if they choose to drink.
Insulin therapy should never be stopped abruptly, particularly in patients with Type 1 diabetes. Sudden discontinuation can lead to severe hyperglycemia and diabetic ketoacidosis (DKA), a life-threatening condition. If a change in therapy is needed, it must be done under the strict supervision of a healthcare provider with a clear plan for transitioning to an alternative medication.
> Important: Discuss all your medical conditions, including any history of heart, kidney, or liver disease, with your healthcare provider before starting Insulin Aspart.
Insulin Aspart does not typically interfere with standard laboratory tests. However, it will naturally lower serum glucose and may lower serum potassium levels, which are the intended pharmacodynamic effects rather than an analytical interference.
For each major interaction, the management strategy involves more frequent blood glucose monitoring and proactive dose adjustments under the guidance of a healthcare professional.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking to prevent dangerous interactions.
There is a potential for cross-sensitivity between different types of insulin analogs. If a patient has had a severe allergic reaction to Insulin Lispro or Insulin Glulisine, they should be monitored closely when starting Insulin Aspart, although the specific molecular differences often mean a patient can tolerate one analog even if they are sensitive to another.
> Important: Your healthcare provider will evaluate your complete medical history, including any previous reactions to insulin products, before prescribing Insulin Aspart.
In patients 65 years and older, the risk of hypoglycemia is higher. This may be due to age-related declines in kidney function, which slows insulin clearance, or the presence of other comorbidities. Geriatric patients may also have reduced awareness of hypoglycemic symptoms. Healthcare providers typically recommend a more conservative dosing approach and less stringent A1c targets for older adults to avoid the dangers of severe falls or cognitive impairment associated with low blood sugar.
Patients with renal impairment are at an increased risk for hypoglycemia. The kidneys are responsible for roughly 30% to 80% of insulin clearance. As the Glomerular Filtration Rate (GFR) declines, the half-life of Insulin Aspart increases. Dose reductions are often necessary when GFR falls below 50 mL/min, and frequent glucose monitoring is mandatory.
The liver is the primary site for the degradation of endogenous and exogenous insulin. In patients with hepatic cirrhosis or other forms of liver failure, the clearance of Insulin Aspart may be reduced, necessitating lower doses. Close clinical monitoring is required to prevent prolonged insulin action and subsequent hypoglycemia.
> Important: Special populations require individualized medical assessment and frequent follow-ups with an endocrinology specialist.
| Bioavailability | High (Subcutaneous) |
| Protein Binding | 0% - 9% |
| Half-life | ~81 minutes |
| Tmax | 40 - 50 minutes |
| Metabolism | Liver, Kidney, Muscle |
| Excretion | Renal (trace amounts) |
Insulin Aspart is classified as a rapid-acting insulin analog within the therapeutic class of antidiabetic agents. It is grouped with other rapid-acting analogs such as Insulin Lispro (Humalog) and Insulin Glulisine (Apidra). These medications are distinct from short-acting (Regular), intermediate-acting (NPH), and long-acting (Glargine, Detemir) insulins based on their pharmacokinetic properties.